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Objective: To test the hypothesis that in vivo transgene expression mediated by single intra-articular
injection of adeno-associated virus serotype 2 (AAV2) persists within intra-articular tissues 1 year
post-injection and can be externally controlled using an AAV2-based tetracycline-inducible gene regu-
lation system containing the tetracycline response element (TRE) promoter.
Methods: Sprague Dawley rats received intra-articular injections of AAV2-cytomegalovirus (CMV)-
enhanced green ﬂuorescent protein (GFP) and AAV2-CMV-luciferase (Luc) into their right and left knees,
respectively. Luciferase expression was evaluated over 1 year using bioluminescence imaging. After
sacriﬁce, tissues were analyzed for GFPþ cells by ﬂuorescent microscopy. To study external control of
intra-articular AAV-transgene expression, another set of rats was co-injected with AAV2-TRE-Luc and
AAV2-CMV-reverse-tetracycline-controlled transactivator (rtTA) into the right knees, and AAV2-CMV-Luc
and AAV2-CMV-rtTA into the left knees. Rats received oral doxycycline (Dox), an analog of tetracycline,
for 7 days. Luciferase expression was assessed by bioluminescence imaging.
Results: Luciferase expression was localized to the injected joint and persisted throughout the 1-year
study period. Abundant GFPþ cells were observed within intra-articular soft tissues. Transgene
expression in AAV2-TRE-Luc injected joints was upregulated by oral administration of Dox, and down-
regulated following its removal, at 14 days and 13 months post-AAV injection.
Conclusions: This longitudinal in vivo study shows that sustained and stable AAV-mediated intra-articular
transgene expression can be achieved through a single intra-articular injection and can be controlled using
a tetracycline-controlled inducible AAV system in a normal rat knee model. Highly regulatable long-term
intra-articular transgene expression is of potential clinical utility for development of treatment strategies
for chronic intra-articular disease processes such as inﬂammatory and degenerative arthritis.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Prevention of articular cartilage degradation or treatment of its
damage in arthritis remains challenging due to the limited self-
repair potential of articular cartilage. Currently, no therapeutic
methods exist for complete re-establishment of cartilage function.
Delivery of therapeutic agents that could promote articular carti-
lage repair or prevent its further degradation once damaged is an
attractive therapeutic option. Protein biologics can be delivered
systemically, or locally by direct injection or through polymer based
delivery systems1. However, due to the short half-life of proteins,
administration of supra-physiological doses and/or repeatedC.R. Chu, Kaufmann Medical
15213, USA. Tel: 1-412-605-
s Research Society International. Pdelivery are often necessary, signiﬁcantly increasing the cost of
these approaches. An attractive alternative is to deliver the genetic
information to cells within the joint and engineer them to produce
the therapeutic protein in situ.
Naked DNA, retrovirus, adenovirus, and herpes virus-based
vectors have been explored for gene transduction in vivo; however,
most were rendered suboptimal due to safety, efﬁcacy, and duration
issues. Recombinant adeno-associated virus (AAV) derived from an
endemic and non-pathogenic parvovirus is emerging as a promising
delivery vehicle for musculoskeletal tissues, with the advantages of
sustained transgene expression, reduced potential for host immune
response, and the capacity to transduce both dividing and non-
dividing cells in vitro and in vivo2. Different serotypes of AAV exist,
each having different preferential targets2,3. AAV5 has better trans-
duction efﬁciency in rodent arthritic joints; however, AAV2 is
currently used in human clinical trials for arthritis4e7.ublished by Elsevier Ltd. All rights reserved.
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implantation in vivo. Although this has led to cartilage repair in
animal models8e12, culturing cells ex vivo prolongs the time before
treatment and is also very expensive in a clinical setting. An alter-
native method would be to deliver the genetic material intra-
articularly by direct injection and rely on the cells within the joint
to produce the therapeutic factor. AAV vectors have a strong tropism
for synoviocytes in vitro13e16. However, few studies have identiﬁed
the exact in vivo localization of the transgene, after intra-articular
injection of AAV17e22. It is important to identify which cells or
tissues are infected by AAV after intra-articular injection and to use
this information to develop optimal treatment strategies for intra-
articular disease processes such as inﬂammatory and degenerative
arthritis.
Knowledge of the duration of transgene expression is also
important to develop efﬁcient therapies. It has been reported that
parkinsonian nonhuman primates having received AAV2 encoding
human L-amino acid decarboxylase (L-DOPA) into their brains were
still expressing the transgene after 8 years23. AAV-mediated eryth-
ropoietin delivery to rhesus monkey skeletal muscle has led to
transgene expression for more than 6 years24. Long-term transgene
expressionmay be critical for disease treatment, butmay not be ideal
for cartilage repair strategies, where a growth factor may only be
needed for a limited time period. In cases where a growth factor is
needed for a speciﬁc period of time or concentration, it may be
advantageous to use an inducible gene expression system,where the
transgene expression can be controlled pharmacologically by oral
administration of the inducing agent. The tetracycline-inducible gene
regulation system has been efﬁcient both in vitro and in vivo24e26.
Doxycycline (Dox), an analog of tetracycline, is widely accepted as an
inducer due to its safe use in humans27. Only few studies have
investigated the use of an AAV-based tetracycline-inducible gene
system in the knee joint after direct injection.
Given the potential translational value of AAV for human clinical
use, the aim of the present study was to investigate the presence,
persistence, and ability to externally control transgene expression
when using AAV2 delivered by a single intra-articular injection into
the rat diarthrodial joint. The immunocompetent rat was chosen
since it is a good animal model for future studies that will test the
repair of articular cartilage, the prevention of its degradation, or the
treatment of inﬂammatory arthritis by AAV-mediated gene therapy.
Materials and methods
AAV vector production
Double-stranded serotype 2 AAV (AAV2) vectors were produced
using the three-plasmid cotransfection method28. Depending on the
AAV2 vector being produced, the ﬁrst plasmid used was either the
AAV-cytomegalovirus (CMV)-Luc plasmid with the luciferase (Luc)
gene driven by the CMV promoter, the AAV-CMV-enhanced green
ﬂuorescent protein (GFP) plasmid, the AAV-CMV-reverse-tetracy-
cline-controlled transactivator (rtTA) plasmid, or the AAV-TRE-Luc
plasmid with the Luc gene driven by the tetracycline response
element (TRE) promoter. The second plasmid used in the cotrans-
fectionwas the pXX6 plasmid, which contains the helper genes from
adenovirus, and the third plasmid was the pXX2, which supplies
AAV2 rep protein and capsid protein28. Vector puriﬁcation was
performed as previously described and AAV genomic titers were
determined by DNA dot-blot assay28.
In vitro infection of rat articular chondrocytes
Primary rat articular chondrocyteswere extracted from the tibial
and femoral cartilage of 3-month-old male Sprague Dawley rats.Cartilage samples were washed in phosphate buffered saline (PBS;
Invitrogen) with 2% penicillinestreptomycin (pen/strep; Invi-
trogen). To digest the cartilage, thin shavingswere incubated in 0.2%
pronase (Calbiochem) solution in F-12 medium (Invitrogen) sup-
plemented with 5% fetal bovine serum (FBS) and 1% pen/strep for
90 min in a dry 37C incubator. This was followed by overnight
digestion in 0.025% collagenase P (Roche Applied Science) in F-12
medium supplemented with 5% FBS and 1% pen/strep. Recovered
chondrocytes were seeded as monolayers in a T-75 ﬂask in 50%
Dulbecco’s modiﬁed Eagle medium/50% F-12 medium (DMEM/F-
12; Invitrogen) supplementedwith 10% FBS, and 1% pen/strep under
normal growth conditions (37C, 5% CO2). Cells were grown to
passage four and plated onto 96-well plates at a density of 2.0104
cells/cm2 in growth medium (DMEM/F-12, 10% FBS, 1% pen/strep).
On the following day, chondrocytes in plain DMEM/F-12 were
infected with 3.2105 vector genomes per cell (vg/cell) of AAV-
CMV-GFP, AAV-CMV-Luc, or AAV-CMV-rtTAþAAV-TRE-Luc for
1 h, after which the mediumwas changed to growth medium. This
dosewas selected because it gave the greatest gene expression in an
in vitro dose response study ranging from 4104e3.2105 vg/cell
(data not shown). After 2 days, cells infected with AAV-TRE-Luc
were stimulated with Dox at concentrations of 0, 1, or 2 mg/ml for
36 h. Luciferase transgene expression was measured 4 days post-
transduction by adding 50 ml of luciferin (30 mg/ml; D-Luciferin
Fireﬂy, Caliper Life Sciences) per well and imaging after 5 min with
the IVIS 200 optical imaging system (Xenogen Corp., Hopkinton,
MA, USA). GFP signal was visualized on the same day using the epi-
ﬂuorescent Eclipse TE-2000U inverted microscope (Nikon).
Animal experiments
All animal experiments were performed following a University
of Pittsburgh Institutional Animal Care and Use Committee
approved protocol. The study was divided into two parts.
In the ﬁrst study, nine male Sprague Dawley rats (3 months old)
received a 50 ml intra-articular injection containing 2.51010 vg of
AAV-CMV-GFP or AAV-CMV-Luc into the right and left knee joint,
respectively. For longitudinal evaluation of luciferase expression,
rats were anesthetized with isoﬂurane inhalation, followed by
a 50 ml intra-articular injection of luciferin (30 mg/ml). After 5 min,
to allow proper distribution of luciferin, ratswere placed in an IVIS
200 optical imaging system. Photon emissions in the region of
interest were quantiﬁed using Living Image software V.3.0 (Xeno-
gen Corp.), and bioluminescent ﬂux was reported as photons/sec.
Rats were imaged every other week for 4 months, and monthly
thereafter, until 1 year post-AAV injection. Rats were sacriﬁced at
either 1 week (n¼ 1), 2 weeks (n¼ 2), 3 months (n¼ 1), 4 months
(n¼ 1) or 1 year (n¼ 4) after AAV injection. On the day of sacriﬁce,
rats received an intraperitoneal injection of 100 ml of luciferin to
determine whether any signal was present outside of the intra-
articular space. They also received an intra-articular injection of
luciferin and imaged as previously described. The joint was then
opened to image the intra-articular tissues. Tissues within the joint
were also analyzed for GFPþ cells using a ﬂuorescent stereomi-
croscope (MVX-10 MacroView Systems, Olympus, Japan) equipped
with a DP71 camera (Olympus). All GFP images in Fig. 4 had the
contrast increased by the same value in Adobe Photoshop to
improve the GFP signal for print.
In the second animal experiment, the right and left knees of four
male Sprague Dawley rats (3 months old) were divided into
experimental and control groups. In the right knee, each rat received
a 50 ml intra-articular injection containing 2.51010 vg of AAV-TRE-
Luc and 2.5 1010 vg of AAV-CMV-rtTA. In the left knee, each rat
received a 50 ml intra-articular injection containing 2.5 1010 vg of
AAV-CMV-Luc and 2.51010 vg of AAV-CMV-rtTA, to have the same
Fig. 2. Duration of in vivo transgene expression after a single intra-articular injection
of AAV-CMV-Luc was observed and quantiﬁed using bioluminescence imaging to
detect luciferase activity. (A) Bioluminescent images of the left knee joint of a repre-
sentative rat at 14 days, 1 month, 6 months and 1 year after a single intra-articular
injection of AAV-CMV-Luc. (B) Median and interquartile range of bioluminescence
observed in the left knee joint of all rats in the study over 1 year following intra-
articular injection of AAV-CMV-Luc. n¼ 4e8 rats (n¼ 8 at 14 days, n¼ 6 at 1 and
2 months, n¼ 5 at 3 months, and n¼ 4 from 4 months to 1 year). No signiﬁcant
difference was observed between the different time points.
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right knee joint (injected with AAV-TRE-Luc), rats were adminis-
tered drinking water containing Dox at a concentration of 2 mg/ml
for 7 days, followed by its removal. To ensure fresh supply thewater
was replaced every day and protected from light with amber
drinking bottles. Ratswere imaged twice aweek as described above.
Addition of Dox to the drinking water was performed at 14 days, 8
months and 13 months post-AAV injection.
Statistical analysis
In vitro studies were repeated three times with 3e9 replicates. A
representative experiment is shown in Fig. 1 (n¼ 9). In vivo studies
were conducted and data observed using independent animals, with
n¼ 4e8 for Fig. 2 due to animals being sacriﬁced at different time
points during the study and n¼ 4 for Fig. 5. All data are represented
as median and interquartile range boxplots with percentiles calcu-
lated using Tukey Hinge. The signiﬁcant level used was P< 0.05,
unless otherwise noted. Assumptions of parametric datawere tested
for all data: normality of data distribution using ShapiroeWilk test
and homogeneity of variance using Levene’s test. For parametric data
(Fig. 5), one-way analysis of variance (ANOVA) with post-hoc Tukey
was used. For non-parametric independent data (Fig. 1), a Krus-
kaleWallis test and post-hoc pairwise ManneWhitney U with
a Bonferroni correction was used. P-values less than 0.008 (0.05/6
total comparisons) were considered signiﬁcant. For non-parametric
data in the longitudinal study (Fig. 2), Friedman’s ANOVA test was
used with the Wilcoxon test and a Bonferroni correction applied for
post-hoc analysis of each consecutive time point. P-values less than
0.005 (0.05/10 comparisons) were considered signiﬁcant. Statistical
evaluations were performed with SPSS software.
Results
In vitro response of rat articular chondrocytes to AAV2 vectors
GFP expression was visualized in articular chondrocytes infec-
ted with AAV-CMV-GFP as early as 24 h post-infection (data not
shown). Articular chondrocytes infected with AAV-CMV-Luc had
luciferase expression (Fig. 1). Infection of articular chondrocytes
with AAV-TRE-Luc led to weak bioluminescence when no Dox was
added (Fig. 1, AAV-TRE-Luc). This signal was signiﬁcantly increasedFig. 1. In vitro response of rat articular chondrocytes to AAV2. Rat articular chondrocytes
were infected with AAV-CMV-Luc or AAV-TRE-Luc, stimulated with Dox (0, 1 or 2 mg/ml)
for 36 h, and luciferase signal was detected. Upper panel: image of bioluminescence
signal from the cells infected with (left to right) AAV-CMV-Luc, AAV-TRE-Luc (no Dox),
AAV-TRE-Luc stimulated with Dox (1 mg/ml) and AAV-TRE-Luc stimulated with Dox
(2 mg/ml). Lower panel: median and interquartile range of bioluminescence for the
different cell groups. n¼ 9. *P< 0.001 for AAV-TRE-Luc: 1 mg/ml Dox vs AAV-TRE-Luc
and for AAV-TRE-Luc: 2 mg/ml Dox vs AAV-TRE-Luc. #P< 0.001 for AAV-TRE-Luc: 1 mg/
ml Dox vs AAV-CMV-Luc and for AAV-TRE-Luc: 2 mg/ml Dox vs AAV-CMV-Luc.
:P< 0.001 for AAV-TRE-Luc: 2 mg/ml Dox vs AAV-TRE-Luc: 1 mg/ml Dox.when the cells were cultured with Dox at concentrations of 1 mg/ml
and 2 mg/ml for 36 h (Fig. 1, *P< 0.001 for AAV-TRE-Luc: 1 mg/ml
Dox and AAV-TRE-Luc: 2 mg/ml Dox compared to AAV-TRE-Luc).
The bioluminescence observed in vitro with the AAV-TRE-Luc
vector and addition of Dox was also greater than that obtained
with the AAV-CMV-Luc vector (Fig. 1, #P< 0.001 for AAV-TRE-Luc:
1 mg/ml Dox and AAV-TRE-Luc: 2 mg/ml Dox compared to AAV-
CMV-Luc). A signiﬁcant difference was also observed between the
two concentrations of Dox tested (Fig. 1, :P< 0.001 for AAV-TRE-
Luc: 2 mg/ml Dox compared to AAV-TRE-Luc: 1 mg/ml Dox).
Duration of in vivo transgene expression after a single
intra-articular injection of AAV2
The IVIS 200 optical imaging system enabled in vivo tracking of
luciferase expression in the same rat knee joints over a 1-year
period. Bioluminescence was visualized as early as 14 days after
intra-articular injection of AAV-CMV-Luc and persisted in all
animals for 1 year, the study end point. Figure 2(A) shows biolu-
minescent images from a representative animal at 14 days,
1month, 6months, and 1 year after intra-articular injection of AAV-
CMV-Luc. In all study animals, the luciferase signal remained
constant throughout the duration of the study [Fig. 2(B)]. The
contralateral AAV-CMV-GFP-injected knees did not show luciferase
signal during the study. Intraperitoneal injection of luciferin and
imaging before sacriﬁce also indicated that no luciferase signal was
present outside the injected knee area.
Localization of in vivo transgene expression after a single
intra-articular injection of AAV2
To localize luciferase signal, knees were imaged intact [Fig. 3(A)]
and after exposing the intra-articular space [Fig. 3(B)]. Biolumi-
nescence was concentrated in two areas [Fig. 3(B and C)]. The
majority of the signal was found in the exposed infrapatellar fat pad
area, with some signal in the intra-articular space containing the
ligaments and meniscus. No bioluminescence was observed in
articular cartilage.
Tissues retrieved from the AAV-CMV-GFP-injected side provided
more information on the localization of cells expressing the
Fig. 3. Localization of in vivo luciferase expression after a single intra-articular injec-
tion of AAV-CMV-Luc by using the IVIS optical imaging system. (A) Luciferase was
detected in the intact left knee joint. (B) Exposure of the intra-articular space of the
same knee joint in (A) revealed that the luciferase signal was located in two major
areas. (C) A higher magniﬁcation of (B) indicated that the signal was mainly found in
the infrapatellar fat pad and in the soft tissues between the femur and tibia, such as the
ligaments and meniscus.
Fig. 4. GFPþ cells in tissues harvested from the right knee joint of rats injected with
AAV-CMV-GFP and imaged with a stereomicroscope. (A) Brightﬁeld image (left panel)
of meniscal tissue with the area located within the square enlarged to show the GFPþ
cells (right panel). (B) Brightﬁeld image (left panel) of tibial plateau. Area within the
square is magniﬁed in the right panel and shows GFPþ cells within the soft tissue.
(C) Brightﬁeld image of the trochlea (left panel). GFPþ cells were sparse in articular
cartilage. Two small areas with GFPþ cells were found on the trochlear ridge in this
animal (right panels).
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synovium, infrapatellar fat pad and tissues within the intra-articular
joint space. Figure 4(A) shows a large area of GFPþ cells within
meniscus, while Fig. 4(B) shows GFPþ cells in soft tissues
surrounding the tibial plateau. GFPþ cells could also be seen in
articular cartilage, although fewer cells could be found when
compared to soft tissues. As seen in Fig. 4(C), two small areas con-
taining GFPþ cells were found on the trochlear ridge of the femur.
Large areas of GFPþ cells in articular cartilage were not found in any
of the study animals.
Controlled in vivo transgene expression following a single
intra-articular injection of AAV2
Persistent luciferase expression was observed for the duration of
the experiment, in all knee joints injected with AAV-CMV-Luc
[Fig. 5(A, B, and C)]. Intra-articular injection of AAV-TRE-Luc led to
a weak luciferase signal before addition of Dox to the drinking water
of the rats [Fig. 5(A)]. Fourteen days post-AAV injection, Dox was
added to the drinking water and led to a signiﬁcant increase in the
luciferase signal after 7 days [Fig. 5(B and D), median fold increase of
11.28 and interquartile range of 16.34 (twenty-ﬁfth-percentile¼ 8.20,
seventy-ﬁfth-percentile¼ 19.49) and *P¼ 0.015 compared to Day 0:
Dox ()]. Removal of Dox signiﬁcantly decreased the signal 7 days
later [Fig. 5(C and D), #P¼ 0.023 compared to Day 7: Dox (þ)]. When
measured 8 months post-AAV injection, addition of Dox to the
drinking water of the rats for 7 days increased luciferase expression
by a median fold increase of 4.31 and interquartile range of 5.45
(twenty-ﬁfth-percentile¼ 2.16, seventy-ﬁfth-percentile¼ 6.04)(P¼ 0.099 compared to Day 0: Dox ()). The luciferase signal
returned to pre-Dox values after the inducer had been removed for 7
days. The induction cycle performed 13 months after the initial
injection of AAV also showed increased luciferase signal on the AAV-
TRE-Luc injected side 7 days after addition of Dox to the drinking
water [Fig. 5(E), median fold increase of 38.43 and interquartile
range of 32.46 (twenty-ﬁfth-percentile¼ 27.48, seventy-ﬁfth-
percentile¼ 54.90) and *P¼ 0.003 compared to Day 0: Dox ()].
Removal of Dox decreased the signal to baseline levels [Fig. 5(E),
#P¼ 0.016 compared to Day 7: Dox (þ)].
Discussion
Prevention of articular cartilage degradation or promotion of its
repair in inﬂammatory and degenerative arthritis remains chal-
lenging. Therapeutic strategies that rely on the delivery of growth
factors to enhance repair or inhibitory molecules that would
Fig. 5. Controlled in vivo transgene expression following a single intra-articular injection of AAV2. (A,B,C) Bioluminescent images of a representative rat that received AAV-TRE-Luc
in the right knee and AAV-CMV-Luc in the left knee 14 days prior. Images shownwere taken (A) before addition of Dox to the drinking water (Day 0), (B) 7 days after Dox was added
to the drinking water (Day 7) and (C) 7 days after Dox was removed from the drinking water (Day 14). Luciferase expressionwas stable in the knee joint injected with AAV-CMV-Luc,
but varied with Dox administration in the knee joints injected with AAV-TRE-Luc. (D) Bioluminescence measured in the knee joint 14 days post-AAV-TRE-Luc injection. Biolu-
minescence is represented as a median fold increase over Day 0, when no Dox was present in the drinking water, and interquartile range. Luciferase expression increased with
addition of Dox to the drinking water after 7 days (Day 7: Dox (þ)). *P¼ 0.015 compared to Day 0: Dox (). After removal of Dox from the drinking water for 7 days (Day 14: Dox
()), the luciferase signal decreased. #P¼ 0.023 compared to Day 7: Dox (þ). (E) Median and interquartile range of bioluminescence measured 13 months post-injection with
AAV-TRE-Luc. Luciferase expression increased 7 days after Dox was present in the drinking water (Day 7: Dox (þ)). *P¼ 0.003 compared to Day 0: Dox (). Luciferase expression
decreased 7 days after removal of Dox (Day 14: Dox ()). #P¼ 0.016 compared to Day 7: Dox (þ). n¼ 4 rats.
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should be produced in situ, to obtain a persistent and stable
concentration, thus limiting the need for puriﬁcation processes,
repeated injections, and supra-physiological doses, which are not
cost effective. Gene therapy is a promising alternative to the
delivery of therapeutic factors, as it provides the genetic material
necessary for protein synthesis in situ. In this study, we analyzed
important aspects for efﬁcient intra-articular gene delivery. These
included the persistence and localization of transgene expression
after a single intra-articular injection of AAV2, as well as the ability
to control the transgene expression over time when using an
inducible AAV2 vector.
Efﬁcacy of AAV2 for in vitro chondrocyte transduction was
evaluated using GFP and luciferase as reporter genes. In accordance
with other studies on mice, rabbit, equine and human
chondrocytes21,29e31, rat articular chondrocytes were also capable
of uptaking the AAV2 vector and producing the transgene protein,
suggesting that AAV2 could be used to infect rat chondrocytes
in vivo. The ability to induce transgene expression with addition of
Dox to the cell culture medium demonstrated the potential to
control the timing of transgene expression.
Studies in nonhuman primates indicate that administration of
AAV to the brain leads to transgene expression for as long as 8 years23,
yet fewstudies have assessed the persistence of transgene expression
after AAV administration to the rat knee joint past a few
months16,18,22,32. Intra-articular injections into the rat stiﬂe joint,
while challenging, have previously been reported by our group and
others18,19,32,33. Given this experience, we believe that AAV was
delivered intra-articularly in this study, although it is possible that
some leakage or partial extra-articular injection may have occurred.
By using bioluminescence, the same animal could be imaged
repeatedly, providing a clear proﬁle of transgene persistence and
biodistribution. All animals had stable luciferase transgene expres-
sion for up to 1 year following intra-articular injection of AAV-CMV-
Luc. A recent study employing recombinant lentivirus or adenovirus
vectors did not observe such stable transgene expression in knees of
immunocompetent rats34. They observed strong transgene expres-
sion that diminished over a 3-week period. Injection of the same
vectors into athymic rats led to an initially high transgene expression,which decreased to 20% and remained at that level for 6 months34.
Prolonged transgene expression in the current study suggests lower
immunogenicity of AAV2 than lentivirus or adenovirus. Stability of
transgene expression following AAV2 injection into the rat knee joint
supports a potential role for AAV2 gene therapy in treatment strat-
egies for inﬂammatory or degenerative arthritis by facilitating the
synthesis of therapeutic factors within the joint space.
Consistent with previous reports of AAV injection into the knee
joint of various animals, both luciferase and GFP transgene
expressions were mostly localized to soft tissues16,17,19,20,22. GFP
imaging with the stereomicroscope provided a more precise
localization than the bioluminescence imaging system and indi-
cated that few sparse areas of GFPþ cells could be found in
articular cartilage. A recent study employing self-complementary
AAV2 injected into the intra-articular joint of guinea pigs also
demonstrated transgene expression by articular chondrocytes20.
Previous studies using AAV have shown higher levels of transgene
expression in diseased cartilage compared to normal cartilage17,19.
Seeing that intact and undamaged articular cartilage is unlikely to
require treatment, future studies will test AAV in rat models of
articular cartilage damage, as it will more closely mimic the
osteoarthritic environment. Abundant transgene expression in
soft tissues suggests that cells within these tissues, such as those
within the infrapatellar fat pad, can uptake the AAV2 and lead to
transgene expression. Given the low turn over rate of these cells,
intra-articular delivery of AAV2 targeted to soft tissues is of value
for anti-inﬂammatory treatment strategies for arthritic condi-
tions. For articular cartilage repair, it may be necessary to target
more speciﬁcally the chondrocytes. This may be especially
important if delivering genes encoding for bone morphogenetic
proteins, as their expression in soft tissues could result in ectopic
mineralization. We and others are exploring strategies for tar-
geted delivery of transgenes to articular chondrocytes and chon-
dral defects12,35,36.
Lack of luciferase signal in the contralateral control knee that did
not receive AAV-CMV-Luc, and lack of signal anywhere else in the
animal suggests that intra-articular injection limits AAV2 delivery
to tissues within the joint and does not travel systemically. This is
advantageous, as bioactive factors present from viral transgene
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possibly lead to negative side effects.
The dose of AAV used in this study of 2.51010 vg/knee jointwas
chosen based onwhat has previously been shown to be effective in
rats32. This prior study employed 1010 vg of AAV/rat knee joint and
reported transgene expression for at least 100 days. The dose chosen
for our current rat study will need to be increased in order to be
effective in a human joint which is larger in size and in volume of
synovial ﬂuid, resulting in a larger volume of distribution.
Others have shown that it is feasible to administer AAV to
humans through intra-articular injection. Human clinical trials for
rheumatoid arthritis using a recombinant, single-stranded AAV2
vector have performed intra-articular injections at doses ranging
from 1011 to 1013 vg/ml and 5 ml was injected per knee joint7,37. The
authors reported these dosages to be safe and feasible, and although
some improvement in patient-reported outcomes was observed,
the transgene expressionwas not found to be sufﬁcient. It should be
noted that humans have serum IgG and neutralizing factors against
different types of AAV, representing a limiting factor to AAV gene
therapy38. In moving towards direct intra-articular injection of AAV
to larger joints, it will be important to determine the optimal dose of
AAV to deliver and the serotype that will face the least amount of
neutralizing antibodies.
Studies involving inducible gene therapy for musculoskeletal
application have mainly focused on genetic engineering of cells
ex vivo, followed by their implantation in vivo25,39e41. Direct viral
gene delivery is easier to administer, and does not require the
additional time and cost associated with ex vivo cell-mediated gene
delivery. As shown in this study, the transgene expression can last
for up to a year, which is not the case with implanted cells12. By
persisting for a prolonged period of time, there is the possibility to
perform multiple cycles of transgene expression with a single
injection of AAV, as shown in this study.
We observed increased transgene expression with addition of
Dox to the drinking water and reduction of transgene expression
following its removal at both 14 days and 13 months post-AAV
injection. A similar trend was observed after 8 months. These data
demonstrate the persistence of the transgene and controllability of
its expression. The variability in observed transgene expression
between the 14 days, 8 months and 13 months time points could
reﬂect type II error due to the small sample size or potentially be
related to a difference in Dox intake. Adding Dox to the drinking
water while simple and shown in this study to be capable of
controlling in vivo intra-articular transgene expressionmay however
lead to some degree of variability since free water intake is less well
controlled than oral administration as a pill or measured suspension.
Future studies with inducible gene expression systems may need to
use direct injection of Dox in small animals and oral suspension or
pill administration in larger animals.
Induction of gene expression 13 months post-AAV injection is of
clinical relevance when a therapeutic protein needs to be re-
administered to further promote cartilage repair, or in cases where
cartilage resumes degrading or inﬂammation increases and another
roundof treatment is necessary. An inducible gene expression system
is also of interest for the delivery of multiple factors. Different bio-
logical molecules could be synthesized at different time points,
depending on the regulatory transcriptional activator. This would
provide a controlled environment for cartilage repair, wheremultiple
growth factors are involved. A limitation of the inducible AAV2 gene
expression system used in this study is the observed leakiness
without the addition of Dox. This can potentially be addressed in
future studies by newer rtTA vectors that have been developed to
reduce basal activity and that require less Dox to be activated42.
In summary, AAV2 delivered by a single intra-articular injection
to a normal rat knee joint led to persistent and stable transgeneexpression that was mainly localized to soft tissues of the joint,
with some expression in chondrocytes. Intra-articular injection of
an inducible AAV2 vector demonstrated the ability to regulate
in vivo transgene expression by oral administration of Dox,
a compound that is safely used in humans. This regulation was
possible immediately after delivering the AAV to the knee joint, and
13 months later. Ability to achieve stable yet highly regulatable
long-term intra-articular transgene expression is of potential
clinical utility for development of new treatment strategies for
intra-articular disease processes such as inﬂammatory and
degenerative arthritis.
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